Embecta (NASDAQ:EMBC) Insider Purchases $99,800.00 in Stock

Embecta Corp. (NASDAQ:EMBC) insider Jeffrey Mann acquired 20,000 shares of the company’s stock in a transaction on Wednesday, August 12th. The stock was bought at an average cost of $4.99 per share, with a total value of $99,800.00. Following the completion of the acquisition, the insider directly owned 262,915 shares in the company, valued at approximately $1,311,945.85. This represents a 8.23% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at this link.

Embecta Stock Performance

EMBC opened at $5.10 on Friday. The firm has a market cap of $288.97 million, a P/E ratio of 3.45 and a beta of 0.81. Embecta Corp. has a 52-week low of $2.77 and a 52-week high of $15.55. The business’s fifty day moving average is $3.50 and its 200-day moving average is $6.41.

Embecta (NASDAQ:EMBC) last issued its quarterly earnings results on Friday, August 7th. The company reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.29. The company had revenue of $271.70 million for the quarter, compared to analysts’ expectations of $254.53 million. Embecta had a negative return on equity of 19.25% and a net margin of 8.59%.Embecta’s revenue was down 8.1% on a year-over-year basis. During the same quarter last year, the business earned $1.12 earnings per share. Embecta has set its FY 2026 guidance at 1.800-1.900 EPS. On average, research analysts predict that Embecta Corp. will post 1.84 earnings per share for the current fiscal year.

Embecta Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 15th. Shareholders of record on Thursday, August 27th will be paid a dividend of $0.01 per share. This represents a $0.04 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date is Thursday, August 27th. Embecta’s dividend payout ratio is presently 2.70%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. Weiss Ratings cut shares of Embecta from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday, August 3rd. Wall Street Zen lowered shares of Embecta from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 9th. Mizuho decreased their price objective on shares of Embecta from $12.00 to $5.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 6th. Bank of America lowered their price objective on shares of Embecta from $11.00 to $3.00 and set an “underperform” rating for the company in a research report on Monday, May 18th. Finally, Zacks Research upgraded Embecta from a “strong sell” rating to a “hold” rating in a research note on Friday, July 17th. Three research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Reduce” and an average target price of $11.00.

Embecta News Roundup

Here are the key news stories impacting Embecta this week:

• Positive Sentiment: CEO Devdatt Kurdikar, CFO Jacob Elguicze and director Jeffrey Z. Mann collectively purchased 70,000 shares worth approximately $334,200 on August 12. The insider buying could signal that management and the director believe Embecta’s shares are undervalued after their steep decline. SEC insider transaction filing
• Neutral Sentiment: Embecta also disclosed a quarterly dividend of $0.01 per share, or $0.04 annualized, with a yield of roughly 0.8%. The modest payout is unlikely to be a major near-term stock catalyst but may appeal to income-focused investors. Embecta dividend and insider trading report
• Neutral Sentiment: Multiple law firms, including Hagens Berman, Bronstein Gewirtz & Grossman, Kaplan Fox, Faruqi & Faruqi and Rosen, reminded investors that August 17 is the deadline to seek lead-plaintiff status. The notices target investors who purchased EMBC securities between November 25, 2025, and May 4, 2026, and mostly repeat previously reported information. Hagens Berman class action deadline notice
• Negative Sentiment: The underlying securities class action alleges that Embecta and certain executives misrepresented the commercial stability of its insulin pen-needle business and issued misleading fiscal 2026 guidance. If the claims gain traction, the company could face legal expenses, reputational damage and further questions about management credibility. The allegations have not been proven in court. Hagens Berman lawsuit alert

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. SG Americas Securities LLC lifted its holdings in shares of Embecta by 138.4% in the first quarter. SG Americas Securities LLC now owns 1,038,948 shares of the company’s stock worth $9,184,000 after acquiring an additional 603,106 shares during the last quarter. Walleye Capital LLC bought a new stake in shares of Embecta during the 1st quarter valued at approximately $7,013,000. Universal Beteiligungs und Servicegesellschaft mbH grew its holdings in shares of Embecta by 1,068.0% during the 4th quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 143,616 shares of the company’s stock valued at $1,708,000 after purchasing an additional 131,320 shares during the last quarter. UBS Group AG increased its position in Embecta by 200.8% during the 4th quarter. UBS Group AG now owns 630,994 shares of the company’s stock worth $7,496,000 after purchasing an additional 421,254 shares in the last quarter. Finally, LSV Asset Management increased its position in Embecta by 92.5% during the 4th quarter. LSV Asset Management now owns 552,582 shares of the company’s stock worth $6,565,000 after purchasing an additional 265,482 shares in the last quarter. Institutional investors own 93.83% of the company’s stock.

Embecta Company Profile

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.